Arrowhead Pharmaceuticals (NASDAQ:ARWR) Sees Large Volume Increase - What's Next?

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Get Free Report) saw unusually-strong trading volume on Monday . Approximately 1,800,420 shares traded hands during mid-day trading, an increase of 14% from the previous session's volume of 1,584,599 shares.The stock last traded at $15.28 and had previously closed at $16.76.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the stock. Chardan Capital reaffirmed a "buy" rating and set a $60.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Tuesday, May 13th. Wall Street Zen lowered Arrowhead Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, July 18th. HC Wainwright reissued a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a report on Tuesday, May 20th. Finally, Citigroup dropped their price objective on Arrowhead Pharmaceuticals from $21.00 to $17.00 and set a "neutral" rating on the stock in a report on Tuesday, May 13th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $43.71.

Arrowhead Pharmaceuticals Trading Up 2.1%

The company has a market cap of $2.25 billion, a P/E ratio of -11.61, a P/E/G ratio of 18.72 and a beta of 0.93. The business has a fifty day simple moving average of $16.37 and a 200 day simple moving average of $16.25. The company has a debt-to-equity ratio of 0.31, a quick ratio of 5.15 and a current ratio of 5.15.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The biotechnology company reported $2.75 EPS for the quarter, topping analysts' consensus estimates of ($0.06) by $2.81. The business had revenue of $542.71 million during the quarter, compared to analyst estimates of $116.27 million. During the same period in the prior year, the firm earned ($1.02) EPS. Analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -2.42 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. GAMMA Investing LLC raised its position in shares of Arrowhead Pharmaceuticals by 297.6% during the 1st quarter. GAMMA Investing LLC now owns 2,175 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 1,628 shares during the period. GF Fund Management CO. LTD. bought a new position in Arrowhead Pharmaceuticals during the 4th quarter worth $49,000. CWM LLC increased its position in Arrowhead Pharmaceuticals by 134.3% in the first quarter. CWM LLC now owns 4,401 shares of the biotechnology company's stock worth $56,000 after buying an additional 2,523 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its stake in Arrowhead Pharmaceuticals by 29.5% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,335 shares of the biotechnology company's stock valued at $84,000 after buying an additional 1,214 shares during the last quarter. Finally, Mackenzie Financial Corp acquired a new position in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at $137,000. Institutional investors own 62.61% of the company's stock.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.